News

Roche considers licensing companies to make oseltamivir

BMJ 2005; 331 doi: 10.1136/bmj.331.7523.981 (Published 27 October 2005)
Cite this as: BMJ 2005;331:981.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. New York

    With the gradual spread of avian influenza from East Asia to Europe, many countries were this week seeking supplies of the antiviral drug oseltamivir (Tamiflu), which lessens the effects of flu when taken at an early stage of the illness.

    Cipla, an Indian company which specialises in generic drugs, said last week that it would make its own generic version of the drug. Cipla said it could market the drug by December and could make a million 10 capsule courses of treatment by next July, a report in New Scientist says (2005;188: 14). …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular